Innovision’s IPO has been extended to March 17 after 32% subscription, reflecting weak investor interest; the price band was revised lower, while revenue growth is strong but margins remain thin.
Pharma, Auto, and IT: Pankaj Pandey shares sectoral insights amid global challenges
Pankaj Pandey shares insights on Indian sectors facing US tariffs. He sees limited impact on pharma growth but potential benefits for Jubilant Pharma and Piramal